RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis — Stella

View on ClinicalTrials.gov

Recruiting

Back to Melanoma trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

United States

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Key details

Phase

Very early testing

Sponsor

Yana Najjar

Collaborators

Replimune, Inc.

Enrollment target

~25 participants

Started

March 2024

Primary completion

March 2028

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.